TCRX logo
TScan Therapeutics, Inc.(TCRX)
$0.34—Stale · unknown old

Consensus

Hold3.00 / 54 ratings · Strong Buy 0 · Buy 0 · Hold 4 · Sell 0 · Strong Sell 0
Avg target $1.00+194.1%Median $1.00High $1.00Low $1.002 targets in the last 12 months

Price vs average target

Revenue and EPS estimates

ReportedConsensus estimates
Fiscal periodFY2023Dec '23FY2024Dec '24FY2025Dec '25FY2026Dec '26FY2027Dec '27FY2028Dec '28FY2029Dec '29FY2030Dec '30
Revenue (M)21.02.810.34.53.320.731.978.7
Growth YoY+101.6%−86.6%+266.7%−56.4%−27.2%+533.1%+53.6%+146.9%
High estimate–––9.85.721.755.2136.2
Low estimate–––1.82.319.822.054.2
Analysts–––43422
EPS, adjusted−1.89−1.14−1.00−0.99−0.71−0.64−0.55−0.41
Growth YoYn/mn/mn/mn/mn/mn/mn/mn/m
High estimate–––−0.59−0.25−0.27−0.33−0.25
Low estimate–––−1.70−1.05−1.15−1.08−0.81
Analysts–––44311

Consensus mean of analyst estimates. EPS is adjusted (street) EPS, the basis analysts forecast; annual actuals are the sum of the four reported quarters. Growth compares with the same period a year earlier; n/m where the prior period was a loss.

Brokers

4 firms active in the last 12 months
FirmAnalystRatingPrev ratingTargetPrev targetChgUpsideDate
H.C. WainwrightAndres MaldonadoNeutralBuy$1.00––+194%Sep 8
Wedbush–NeutralOutperform$1.00––+194%Sep 3
Needham–HoldBuy––––Sep 2
BTIG–NeutralBuy––––Nov 4, 2025
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.